Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
暂无分享,去创建一个
H. Ueno | J. Furuse | Y. Ohashi | K. Mizumoto | Masao Tanaka | A. Cheng | M. Ikeda | H. Baba | S. Egawa | K. Sugimori | Jen‐Shi Chen | Taketo Yamaguchi | M. Kitano | T. Okusaka | K. Yamao | T. Hatori | T. Ioka | H. Yanagimoto | M. Sho | N. Boku | S. Ohkawa | A. Funakoshi | A. Fukutomi | A. Sato | T. Shimamura
[1] J. Chabot,et al. Chemotherapy: Metastatic pancreatic cancer—is FOLFIRINOX the new standard? , 2011, Nature Reviews Clinical Oncology.
[2] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[3] E. Van Cutsem,et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.
[4] B. Goh,et al. Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patients , 2011, Cancer science.
[5] H. Ueno,et al. A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer , 2007 .
[6] A. Jemal,et al. Global Cancer Statistics , 2011 .
[7] R. Schilsky,et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Khorana,et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Ellis,et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Scheithauer,et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Catalano,et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Saif,et al. S-1: a promising new oral fluoropyrimidine derivative , 2009, Expert opinion on investigational drugs.
[13] T. Shirasaka. Development History and Concept of an Oral Anticancer Agent S-1 (TS-1®): Its Clinical Usefulness and Future Vistas , 2008, Japanese journal of clinical oncology.
[14] E. Van Cutsem,et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Ueno,et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer , 2008, Cancer Chemotherapy and Pharmacology.
[16] J. Furuse,et al. A late phase II study of S-1 for metastatic pancreatic cancer , 2008, Cancer Chemotherapy and Pharmacology.
[17] W. Scheithauer,et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Einsele,et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] H. Ueno,et al. An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer , 2005, Oncology.
[21] T. Ishihara,et al. Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer , 2005, British Journal of Cancer.
[22] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[23] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[25] Ron Brookmeyer,et al. A Confidence Interval for the Median Survival Time , 1982 .
[26] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .